公开(公告)号：US20200071306A1

公开(公告)日：2020-03-05

申请号：US16553818

申请日：2019-08-28

Applicant: Pfizer Inc.

Inventor： William Paul Esler ,  Trenton Thomas Ross

IPC: C07D405/14 ,  C07D471/10

Abstract: The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.

公开(公告)号：US12247022B2

公开(公告)日：2025-03-11

申请号：US17498256

申请日：2021-10-11

Applicant: Pfizer Inc.

Inventor： William Paul Esler ,  Trenton Thomas Ross

IPC: C07D405/14 ,  A61K45/06 ,  C07D471/10

Abstract: The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.

公开(公告)号：US11254660B2

公开(公告)日：2022-02-22

申请号：US16553818

申请日：2019-08-28

Applicant: Pfizer Inc.

Inventor： William Paul Esler ,  Trenton Thomas Ross

IPC: C07D405/14 ,  C07D471/10 ,  A61K45/06

Abstract: The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.

公开(公告)号：US20220023299A1

公开(公告)日：2022-01-27

申请号：US17498256

申请日：2021-10-11

Applicant: Pfizer Inc.

Inventor： William Paul Esler ,  Trenton Thomas Ross

IPC: A61K31/506 ,  A61K31/438 ,  A61K9/00 ,  A61P1/16

Abstract: The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.